In glioblastoma, BCL6 represents a key downstream target of MED12, with the increased BCL6 protein able to suppress TP53-mediated apoptosis [107], while it lies downstream of KRAS in lung cancer [108]. Here, BCL6 is linked to lung carcinoma.